Experience reveals that there is significant noncompliance with self-administered medication, especially in chronic conditions such as cancer. Noncompliance transcends the boundary of disease categories and age group. However, this is most prevalent during the adolescent years when the process of tr
Evidence-based medicine in migraine prophylactic treatment in childhood and adolescence
β Scribed by Umberto Balottin; Matteo Ferri; Cristiano Termine
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 122 KB
- Volume
- 68
- Category
- Article
- ISSN
- 0272-4391
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Migraine is a common and disabling disorder, affecting children, adolescents, and adults. Prophylactic therapy should be considered when specific clinical conditions are fulfilled. Its goal is to reduce the frequency and duration of the attacks as well as the severity of pain, thus allowing patients to regain routine activities and ameliorating their quality of life. Using the principles of evidenceβbased medicine, a review of available published data on the efficacy and safety of prophylactic treatments for migraine in children and adolescents is presented. Currently, only flunarizine and psychologically based interventions (e.g., relaxation training, biofeedback, and psychotherapeutic techniques) may be effective in migraine prophylaxis in children and adolescents. Owing to the paucity of evidence, there is a need for large, controlled, randomized, and masked trials. Clinical researchers should consider that migraine, especially in childhood and adolescence, is a complex condition, resulting from the interaction between biological, psychological, and environmental factors. Specific events, constitutional predisposition, individual and environmentalβemotional dynamics can play a significant role in the genesis and evolution of pain. Ageβrelated characteristics such as prevalence, diagnosis, quality of life, and therapy should be considered designing future studies. Drug Dev Res 68:461β468, 2007. Β© 2008 WileyβLiss, Inc.
π SIMILAR VOLUMES